Stockreport

Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis (NASH)

Gilead Sciences, Inc.  (GILD) 
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
PDF - Oral ACC Inhibitor Led to Significant Reductions in Measures of Liver Fat and Fibrosis - - Results from the GS-0976 Phase 2 Study and 18 Other [Read more]